Inovio Pharmaceuticals Valuation
Is INO * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of INO * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: INO * (MX$83) is trading below our estimate of fair value (MX$1729.37)
Significantly Below Fair Value: INO * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INO *?
Key metric: As INO * barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is INO *'s PB Ratio? | |
|---|---|
| PB Ratio | 1.5x |
| Book | US$73.54m |
| Market Cap | US$109.36m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 181.9x |
| Enterprise Value/EBITDA | -0.3x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does INO *'s PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.8x | ||
AVTX Avalo Therapeutics | 4.7x | -17.9% | US$104.5m |
INMB INmune Bio | 2.8x | 22.0% | US$108.2m |
GNLX Genelux | 2.8x | 12.0% | US$84.9m |
A084650 LabGenomics | 0.9x | n/a | ₩195.6b |
INO * Inovio Pharmaceuticals | 1.5x | 26.2% | Mex$109.4m |
Price-To-Book vs Peers: INO * is good value based on its Price-To-Book Ratio (1.5x) compared to the peer average (2.8x).
Price to Book Ratio vs Industry
How does INO *'s PB Ratio compare vs other companies in the Global Biotechs Industry?
| 85 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 85 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: INO * is good value based on its Price-To-Book Ratio (1.5x) compared to the Global Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is INO *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate INO *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$83.00 | Mex$215.89 +160.1% | 51.0% | Mex$364.32 | Mex$101.20 | n/a | 6 |
| Nov ’25 | Mex$110.00 | Mex$303.32 +175.7% | 53.9% | Mex$635.53 | Mex$134.81 | n/a | 6 |
| Oct ’25 | Mex$116.00 | Mex$319.64 +175.6% | 50.4% | Mex$629.74 | Mex$152.66 | n/a | 6 |
| Sep ’25 | Mex$150.00 | Mex$319.64 +113.1% | 50.4% | Mex$629.74 | Mex$152.66 | n/a | 6 |
| Aug ’25 | Mex$190.00 | Mex$318.62 +67.7% | 53.4% | Mex$673.74 | Mex$160.01 | n/a | 6 |
| Jul ’25 | Mex$156.56 | Mex$318.62 +103.5% | 53.4% | Mex$673.74 | Mex$160.01 | n/a | 6 |
| Jun ’25 | Mex$166.03 | Mex$318.62 +91.9% | 53.4% | Mex$673.74 | Mex$160.01 | n/a | 6 |
| May ’25 | Mex$195.50 | Mex$320.02 +63.7% | 65.0% | Mex$664.97 | Mex$132.99 | n/a | 4 |
| Apr ’25 | Mex$219.02 | Mex$320.02 +46.1% | 65.0% | Mex$664.97 | Mex$132.99 | n/a | 4 |
| Mar ’25 | Mex$161.00 | Mex$321.41 +99.6% | 81.1% | Mex$682.64 | Mex$76.80 | n/a | 3 |
| Feb ’25 | Mex$91.28 | Mex$325.73 +256.8% | 80.2% | Mex$688.16 | Mex$82.58 | n/a | 3 |
| Nov ’24 | Mex$84.00 | Mex$255.64 +204.3% | 60.0% | Mex$409.02 | Mex$102.25 | Mex$110.00 | 2 |
| Oct ’24 | Mex$84.00 | Mex$255.64 +204.3% | 60.0% | Mex$409.02 | Mex$102.25 | Mex$116.00 | 2 |
| Sep ’24 | Mex$89.88 | Mex$255.64 +184.4% | 60.0% | Mex$409.02 | Mex$102.25 | Mex$150.00 | 2 |
| Aug ’24 | Mex$100.20 | Mex$281.39 +180.8% | 35.4% | Mex$422.08 | Mex$211.04 | Mex$190.00 | 3 |
| Jul ’24 | Mex$85.20 | Mex$281.39 +230.3% | 35.4% | Mex$422.08 | Mex$211.04 | Mex$156.56 | 3 |
| Jun ’24 | Mex$121.32 | Mex$281.39 +131.9% | 35.4% | Mex$422.08 | Mex$211.04 | Mex$166.03 | 3 |
| May ’24 | Mex$168.00 | Mex$301.68 +79.6% | 30.9% | Mex$430.97 | Mex$215.48 | Mex$195.50 | 3 |
| Apr ’24 | Mex$174.00 | Mex$301.68 +73.4% | 30.9% | Mex$430.97 | Mex$215.48 | Mex$219.02 | 3 |
| Mar ’24 | Mex$270.00 | Mex$528.69 +95.8% | 20.2% | Mex$679.74 | Mex$453.16 | Mex$161.00 | 3 |
| Feb ’24 | Mex$374.28 | Mex$528.69 +41.3% | 20.2% | Mex$679.74 | Mex$453.16 | Mex$91.28 | 3 |
| Jan ’24 | Mex$342.00 | Mex$528.73 +54.6% | 19.2% | Mex$704.97 | Mex$469.98 | Mex$99.60 | 4 |
| Dec ’23 | Mex$457.32 | Mex$528.73 +15.6% | 19.2% | Mex$704.97 | Mex$469.98 | Mex$85.80 | 4 |
| Nov ’23 | Mex$513.84 | Mex$713.32 +38.8% | 36.5% | Mex$1,188.86 | Mex$475.55 | Mex$84.00 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Zai Lab
US$2.7b
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
ZLAB N
US$611.50
7D
0%
1Y
n/a